重组腺病毒载体与佐剂蛋白异源初免-加强策略评估:以HER2为模型抗原
该研究以HER2为模型抗原,在小鼠中比较复制 competent(ΔPS AdV)与非复制型重组腺病毒载体(AdV)诱导抗原特异性T、B细胞应答的能力,并评估AdV:Her2初免联合古菌体佐剂蛋白加强的异源初免-加强方案。结果显示AdV:Her2单次给药即可诱导强细胞免疫应答,低剂量初免后CD8+ T细胞应答强且不被蛋白加强进一步增强,但SLA:HER2adm加强可拓宽抗体应答。
要点
- AdV:Her2单次给药即可诱导强抗原特异性细胞免疫应答。
- 低剂量AdV:Her2初免后CD8+ T细胞应答强,蛋白加强不进一步增强。
- SLA:HER2adm加强可拓宽抗体应答而不损害CD8+ T细胞应答。
核心结论
- AdV:Her2即使低剂量也能诱导强抗原特异性CD8+ T细胞应答,用SLA佐剂蛋白加强可拓宽抗体应答且不损害CD8+ T细胞应答。
研究设计与样本
- 研究在小鼠中生成表达大鼠HER2/neu的复制 competent(ΔPS AdV)和非复制型重组腺病毒载体(AdV),比较四种剂量和四个时间点的抗原特异性T、B细胞应答。
- 随后评估AdV:Her2初免联合SLA/LA:HER2enc或SLA:HER2adm加强的异源初免-加强方案。
主要发现
- ΔPS AdV:Her2诱导更持久的抗原特异性CD8+ T细胞应答,但AdV:Her2总体诱导更广泛的T、B细胞应答。
- AdV:Her2单次给药诱导强细胞免疫应答,SLA/LA:HER2enc单次给药诱导强抗原特异性IgG滴度。
- 低剂量AdV:Her2初免后单次加强即见强CD8+ T细胞应答,蛋白加强未进一步增强该应答。
- AdV:Her2诱导的CD4+特异性T细胞应答可被SLA:HER2adm加强增强。
- SLA:HER2adm同源接种诱导强抗原特异性抗体应答,三剂SLA:HER2adm与Ad:HER2初免后两剂SLA:HER2adm的总体应答幅度相似。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Induction of strong antigen-specific cell-mediated and humoral responses are critical to developing a successful therapeutic vaccine. Herein, using HER2 as a model antigen, we aim to evaluate a therapeutic vaccine protocol that elicits anti-tumor antibody and cytotoxic T cells to HER2/neu antigen. Replication-competent (ΔPS AdV) and non-replicating recombinant adenoviral vectors (AdV) expressing a rat HER2/neu (ErbB2) oncogene, were generated and compared for four different doses and over four time points for their ability to induce antigen-specific T and B cell responses in mice. Although ΔPS AdV:Her2 vector was shown to induce more durable antigen-specific CD8+ T cell responses, overall, the AdV:Her2 vector induced broader T and B cell responses. Hence the AdV:Her2 vector was used to evaluate a heterologous prime-boost vaccination regimen using rat HER2 protein encapsulated in archaeosomes composed of a semi-synthetic glycolipid (sulfated S-lactosylarchaeol, SLA; and lactosylarchaeol, LA) (SLA/LA:HER2enc) or admixed with archaeosomes composed of SLA alone (SLA:HER2adm). We first tested AdV:Her2 using a prime-boost approach with SLA/LA:HER2enc, and thereafter evaluated a sub-optimal AdV:Her2 dose in a heterologous prime-boost approach with SLA:HER2adm. A single administration of AdV:Her2 alone induced strong cell-mediated immune responses, whereas SLA/LA:HER2enc alone induced strong antigen-specific IgG titers. In mice primed with a suboptimal dose of AdV:Her2, strong CD8+ T-cell responses were observed after a single dose which were not further augmented by protein boost. AdV:Her2 induced CD4+ specific T-cell responses were augmented by SLA:HER2adm. Homologous vaccination using SLA:HER2adm induced strong antigen-specific antibody responses. However, the overall magnitude of the responses was similar with three doses of SLA:HER2adm or Ad:HER2 prime followed by two doses of SLA:HER2adm. We demonstrate that AdV:Her2 is capable of inducing strong antigen-specific CD8+ T cell responses, even at a low dose, and that these responses can be broadened to include antigen-specific antibody responses by boosting with SLA adjuvanted proteins without compromising CD8 T cell responses elicited by AdV priming.
引用
- Haq K, Jia Y, Elahi SM, et al. Evaluation of recombinant adenovirus vectors and adjuvanted protein as a heterologous prime-boost strategy using HER2 as a model antigen. Vaccine. 2019. PMID: 31506193. doi:10.1016/j.vaccine.2019.08.079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。